David Maag

Medicine · Health Sciences

36h-index7.4kcitations125works12.12yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PARP inhibition in cancer therapy(50), Advanced Breast Cancer Therapies(16), Glioma Diagnosis and Treatment(13), Cancer Treatment and Pharmacology(13), RNA and protein synthesis mechanisms(11)

Publications125 total

Evolving Treatment Goals to Achieve Freedom From Attacks and Long-Term Prophylaxis Following a One-Time Treatment With Lonvoguran Ziclumeran (Lonvo-z; NTLA-2002)
Journal of Allergy and Clinical Immunology·2026
Quantitative Systems Biology Modeling Estimates Extent of Excessive Kallikrein Generation in Hereditary Angioedema Patients
Journal of Allergy and Clinical Immunology·2026
Long-Term Durability and Safety of Lonvoguran Ziclumeran (Lonvo-z, NTLA-2002) 50mg in Patients With Hereditary Angioedema
Journal of Allergy and Clinical Immunology·2026
TWO-YEAR DURABILITY/SAFETY OF ONE-TIME LONVOGURAN ZICLUMERAN (LONVO-Z, NTLA-2002) 50MG IN PATIENTS WITH HEREDITARY ANGIOEDEMA
Annals of Allergy Asthma & Immunology·2025
CRISPR-Based NTLA-2002 Improves Quality of Life in Patients With Hereditary Angioedema
Journal of Allergy and Clinical Immunology·2025Open Access
RESULTS FROM A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF CRISPR-BASED THERAPY NTLA-2002 FOR HEREDITARY ANGIOEDEMA
Annals of Allergy Asthma & Immunology·2024· 3 cited
CRISPR-Based Therapy for Hereditary Angioedema
New England Journal of Medicine·2024· 36 citedOpen Access
Data from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)
2024Open Access
Figure S3 from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)
2024Open Access
Supplementary Tables from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)
2024Open Access
Supplementary Figure Legends from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)
2024Open Access
Figure S4 from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)
2024Open Access
Figure S1 from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)
2024Open Access
Figure S2 from Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)
2024Open Access
CRISPR-Cas9 In Vivo Gene Editing of <i>KLKB1</i> for Hereditary Angioedema
New England Journal of Medicine·2024· 143 cited
Supplementary Table S4 from Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors
2023Open Access
Supplementary Table S4 from Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors
2023Open Access
Supplementary Table 1 from PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
2023Open Access
Supplementary Figure 2 from PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
2023Open Access
Supplementary Figure 1 from PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Mikkel A. Algire(10), Jon R. Lorsch(10), Sibylle Loibl(9), Mehra Golshan(9), Otto Metzger(9), Charles E. Geyer(9), Michael Untch(8), William M. Sikov(8), Hope S. Rugo(8), Jens Huober(8), Norman Wolmark(8), Peter Ansell(7), Gϋnter von Minckwitz(6), Danielle Sullivan(6), W. Fraser Symmans(6), Véronique Dièras(6), Michael Friedländer(6), Priya Rastogi(5), Hyo S. Han(5), Bella Kaufman(5)